Interactions on record — worth a quick check against your medications. Based on 3 of 9 ingredients. Check your meds →
Dietary supplement

Bio.Me Oral Ingredients & Drug Interactions

by Invivo

Powder Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Bio.Me Oral is a dietary supplement by Invivo with 9 active ingredients. Its ingredients are commonly taken for digestive health and regularity, diarrhea (including antibiotic-related), irritable bowel syndrome (ibs) symptoms.Based on those ingredients, 182 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Bifidobacterium bifidum W23, B. breve W25. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Bio.Me Oral by Invivo

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 9 active ingredients.
  • “Smile Probiotics” is listed as a grouped ingredient — the label doesn't break down how much of each component you get.

Bio.Me Oral contains nine active ingredients, all probiotic (beneficial bacteria) strains: Bifidobacterium bifidum W23, B. lactis W51, Lactobacillus salivarius W24, L. plantarum W21, Enterococcus faecium W54, L. rhamnosus W71, L. salivarius W57, Streptococcus thermophilus W69, and B. breve W25. These are meant to support your gut bacteria balance.

The powder also contains three inactive ingredients — maize starch, maltodextrin, and hydrolyzed rice protein — which help make the formulation stable.

Does it work?

Not established
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not established

The graded evidence we hold for these ingredients covers different conditions than the ones this product is marketed for, so there's no established rating for its stated use.

Why this rating?
  • The label markets this product for: oral microbiome balance with clinically researched probiotics.
  • We looked for evidence on: Dental plaque, Oropharyngeal candidiasis, Oral mucositis, Oral health, Gum health, Mouth microbiome.
  • The closest evidence on file: Streptococcus Thermophilus is rated "Insufficient Reliable Evidence To Rate" for Oral mucositis (Natural Medicines).
  • Also on file: Bifidobacterium Bifidum is rated "Insufficient Reliable Evidence To Rate" for Dental plaque, Oropharyngeal candidiasis.

The evidence on what these ingredients can do is mixed. B. bifidum is possibly effective for irritable bowel syndrome (IBS) and respiratory tract infections, but we don't have enough data to rate it for hay fever, Alzheimer disease, or anxiety.

B. breve is rated possibly ineffective for age-related cognitive decline and sepsis, and insufficient evidence exists for hay fever, antibiotic-associated diarrhea, or atopic disease. Streptococcus thermophilus has insufficient evidence for antibiotic-associated diarrhea, bacterial vaginosis, fatty liver disease, constipation, diabetes, or diabetic kidney disease.

For the other strains, we hold no effectiveness ratings in our data.

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 3 of the 3 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 3 of 3.
  • General safety write-ups exist for 3 of 3.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

These probiotics are generally well tolerated in healthy people. The main caution: if you have a weakened immune system or are severely ill, check with your doctor before taking this product — rare cases of blood infection (bacteremia) and sepsis have been reported in critically ill or immunocompromised patients, though these are uncommon and haven't been tied specifically to most of these strains.

Bloating and flatulence can occur with probiotics in general, though they haven't been reported specifically from B. bifidum or B. breve. One case of vomiting and fever was reported in a child taking B. bifidum with another probiotic, but it's unclear whether the probiotics caused it.

Pregnancy: B. bifidum and S. thermophilus are rated possibly safe in pregnancy. For B. breve, pregnancy and lactation data aren't on file.

Talk to your doctor before use during pregnancy or breastfeeding.

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 2 of the 3 matched ingredients can interact with medications — Bifidobacterium Breve, Bifidobacterium Bifidum.
  • The most serious interaction on file is rated Moderate.
  • For scale: 182 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

If you're taking antibiotics, separate your dose from this product by a few hours — the probiotics can be killed off if taken together, lowering how well they work. For the five other probiotic strains in this product, we don't hold interaction data, so ask your pharmacist to check those against your specific medications if you take anything else.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with no established evidence rating for its marketed use. Moderate medication interactions have been identified, and safety information is well characterized.

Bio.Me Oral is a multi-strain probiotic that may help with IBS and respiratory infections, though the evidence for many of its uses is still limited. If you take antibiotics, just space this product a few hours apart from your dose.

Anyone with a severely weakened immune system should check with their doctor first. Ask your pharmacist or doctor about whether this fits your needs.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 3 of 9 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Feb 23, 2022.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Bio.Me Oral, straight from the product label.

Brand Invivo
Barcode (UPC) 0710535365955
Net contents 60 Gram(s)
Market status On market
Date entered into DSLD Feb 23, 2022
DSLD ID 259865
Product type Non-nutrient/non-botanical
Supplement form Powder
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegetarian, Adult (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Bio.Me Oral by Invivo, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Gram(s)
Maximum serving Sizes:
1 Gram(s)
UPC/BARCODE
0710535365955
IngredientAmount% DV
Bifidobacterium bifidum W230 NP--
Bifidobacterium lactis W510 NP--
Lactobacillus salivarius W240 NP--
Lactobacillus plantarum W210 NP--
Enterococcus faecium W540 NP--
Lactobacillus rhamnosus W710 NP--
Lactobacillus salivarius W570 NP--
Streptococcus thermophilus W690 NP--
Smile Probiotics0 NP--
B. breve W250 NP--

Other ingredients: Maize Starch, Maltodextrin, hydrolyzed Rice Protein

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
FDA Statement of Identity

Food Supplement

Formulation

Mouthwash with clinically researched probiotics for the oral microbiome

GMO-free

Vegetarian

Storage

Shelf-stable

Store in the original packaging, at room temperature, in a dry place.

Suggested/Recommended/Usage/Directions

Directions: Mix 1g (0.5 tsp) twice daily into 50ml of water. Leave for 1 minute. Stir before swishing in the mouth for 20 seconds before swallowing or spitting out.

Precautions

Do not exceed the recommended dose, unless advised by your healthcare professional.

Do not use if immunocompromised or allergic to any of the ingredients.

When taking antibiotics, wait 2-3 hours before using Bio.Me Oral.

Food supplements are not a substitute for a varied and balanced diet or lifestyle.

Keep out of reach of children.

Seals/Symbols

Certified B Corporation

Carbon Neutral

Probioact Technology

GMP Certified

See for yourself

Bio.Me Oral by Invivo label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Bio.Me Oral by Invivo

These are the 9 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Gram(s) Dosage formPowder Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Smile Probiotics

0 NP per serving

Other (inactive) ingredients: Maize Starch, Maltodextrin, Hydrolyzed Rice Protein. These complete the product’s ingredient list but are not active constituents.

Interaction report

Bio.Me Oral by Invivo Drug Interactions

Want to check YOUR meds against Bio.Me Oral?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
182Drugs
182 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Bio.Me Oral with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Bifidobacterium bifidum W231 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium. bifidum with antibiotic drugs might decrease the effectiveness of B. bifidum.
Since B. bifidum preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. bifidum preparations by at least 2 hours.

Likelihood Probable Evidence D

B. breve W251 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium breve with antibiotic drugs might decrease the effectiveness of B. breve.
Since B. breve preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. breve preparations by at least 2 hours.

Likelihood Probable Evidence D
The maker

Brand information

Manufacturer and brand details for Bio.Me Oral, from the product label.

Invivo

See all Invivo products
Name
Invivo Healthcare
State
UK
ZipCode
GL5 2TE
Web Address
invivohealthcare.com
Pharmacist Counseling Corner

Bio.Me Oral by Invivo: Common Questions

Does Bio.Me Oral by Invivo interact with any medications?
Yes. Based on its ingredients, Bio.Me Oral has a known interaction with 182 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Bio.Me Oral contains 9 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this while I'm on an antibiotic?
You can, but don't take them at the same time. Antibiotics kill probiotics, so space them out by a few hours — ask your pharmacist for the best timing. The antibiotic will still work fine; you're just protecting the probiotic.
Is this safe if I have a weak immune system?
Probiotics are generally well tolerated, but if your immune system is weakened or you're severely ill, check with your doctor first. Rare cases of infection have been reported in very ill patients using probiotics, so it's worth a quick conversation with your provider.
What does Bifidobacterium bifidum do?
B. bifidum is possibly effective for irritable bowel syndrome and respiratory tract infections. For other conditions like hay fever or anxiety, we don't have enough evidence yet to say whether it helps.
Can I take this while pregnant?
Bifidobacterium bifidum and Streptococcus thermophilus are rated possibly safe in pregnancy. For the other strains, we don't have enough safety data. Talk to your doctor or pharmacist before starting, especially during pregnancy.
Does this cause side effects?
Bloating and flatulence can happen with probiotics, but they haven't been specifically reported from these strains. A single case of vomiting and fever was reported in a child, but it's unclear if the probiotics caused it. Most people tolerate these well.
Why is this a powder instead of a capsule?
The product facts don't explain why it's a powder. Ask your pharmacist — the form may affect how you use it or store it.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Bio.Me Oral is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Bio.Me Oral label
Sources

Sources & How We Checked

Bio.Me Oral's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 37 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Bifidobacterium Bifidum 7 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682-7. PubMed
  4. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  5. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  6. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  7. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed

See these in context on the Bifidobacterium Bifidum monograph →

Streptococcus Thermophilus 21 references
  1. Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland 1989-1992. Clin Infect Dis 1996;22:564-6. PubMed
  2. Tynkkynen S, Singh KV, Varmanen P. Vancomycin resistance factor of Lactobacillus rhamnosus GG in relation to enterococcal vancomycin resistance (van) genes. Int J Food Microbiol 1998;41:195-204. PubMed
  3. Klein G, Zill E, Schindler R, et al. Peritonitis associated with vancomycin-resistant Lactobacillus rhamnosus in a continuous ambulatory peritoneal dialysis patient; organism identification, antibiotic therapy, and case report. J Clin Microbiol 1998;36:
  4. Kalima P, Masterton RG, Roddie PH, et al. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996;32:165-7. PubMed
  5. Goldin BR. Health Benefits of probiotics. Br J Nutr 1998;80:S203-7. DOI
  6. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.
  7. MacGregor G, Smith AJ, Thakker B, Kinsella J. Yoghurt biotherapy: contraindicated in immunosuppressed patients? Postgrad Med J 2002;78:366-7. PubMed
  8. Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81.
  9. De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005;24:278-80. PubMed
  10. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47(5):437-9. PubMed
  11. Dolatkhah N, Hajifaraji M, Abbasalizadeh F, Aghamohammadzadeh N, Mehrabi Y, Abbasi MM. Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial. J Health Popul Nutr. 2015;33:25. PubMed
  12. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  13. Sendil S, Shrimanker I, Mansoora Q, Goldman J, Nookala VK. Lactobacillus rhamnosus bacteremia in an immunocompromised renal transplant patient. Cureus. 2020;12(2):e6887. PubMed
  14. Albarillo FS, Shah U, Joyce C, Slade D. Lactobacillus rhamnosus Infection: A single-center 4-year descriptive analysis. J Glob Infect Dis. 2020;12(3):119-123. PubMed
  15. Pasala S, Singer L, Arshad T, Roach K. Lactobacillus endocarditis in a healthy patient with probiotic use. IDCases. 2020;22:e00915. PubMed
  16. Agrawal S, Tuchman ES, Bruce MJ, Theodorou ME. Fatal Lactobacillus endocarditis in a patient with transcatheter aortic valve replacement. BMJ Case Rep. 2020;13(11):e236835.
  17. Antoun M, Hattab Y, Akhrass FA, Hamilton LD. Uncommon pathogen, Lactobacillus, causing infective endocarditis: Case report and review. Case Rep Infect Dis. 2020;2020:8833948. PubMed
  18. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  19. Franko B, Vaillant M, Recule C, Vautrin E, et al. Lactobacillus paracasei endocarditis in a consumer of probiotics. Med Mal Infect. 2013;43(4):171-3. PubMed
  20. Campbell RE, Miller A, Afroze A. Native valve endocarditis secondary to Lactobacillus paracasei bacteremia. Consultant. 2020;60(9):27-8. DOI
  21. Kato K, Funabashi N, Takaoka H, et al. Lactobacillus paracasei endocarditis in a consumer of probiotics with advanced and severe bicuspid aortic valve stenosis complicated with diffuse left ventricular mid-layer fibrosis. Int J Cardiol. 2016;224:157-161. PubMed

See these in context on the Streptococcus Thermophilus monograph →

Bifidobacterium Breve 9 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  4. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr. 2010;156(4):679-81. PubMed
  5. Sakurai Y, Watanabe T, Miura Y, et al. Clinical and bacteriologic characteristics of six cases of Bifidobacterium breve bacteremia due to probiotic administration in the neonatal intensive care unit. Pediatr Infect Dis J 2022;41(1):62-65. PubMed
  6. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  7. Wakabayashi Y, Nakayama S, Yamamoto A, et al. First case of necrotizing fasciitis and bacteremia caused by Bifidobacteriumbreve. Anaerobe 2022;76:102613.
  8. Takeda Y, Ota K, Kondo A, et al. A case of necrotizing fasciitis caused by Bifidobacterium breve. IDCases 2022;31:e01667. PubMed
  9. Suwantarat N, Romagnoli M, Wakefield T, Carroll KC. Ventriculoperitoneal shunt infection caused by Bifidobacterium breve. Anaerobe 2014;28:1-3. PubMed

See these in context on the Bifidobacterium Breve monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring